Controversies in design and interpretation of adjuvant clinical trials

Cancer Investigation

Volumn 28, Issue SUPPL. 1, 2010, Pages 28-34

  Cuzick, Jack ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

anastrozole; aromatase inhibitors; endocrine therapy; exemestane; letrozole; tamoxifen

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; EXEMESTANE; LETROZOLE; PROGESTERONE RECEPTOR; TAMOXIFEN; TAMOXIFEN CITRATE;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RESEARCH; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DISTANT METASTASIS; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EARLY CANCER; EVENT FREE SURVIVAL; HUMAN; INTRADUCTAL CARCINOMA; METHODOLOGY; MONOTHERAPY; OVERALL SURVIVAL; POSTMENOPAUSE; POSTOPERATIVE CARE; PRIORITY JOURNAL; REVIEW; STANDARDIZATION; STATISTICAL ANALYSIS;

AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; ENDPOINT DETERMINATION; FEMALE; HUMANS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RESEARCH DESIGN; TAMOXIFEN;

EID: 77954978444     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.3109/07357907.2010.501633     Document Type: Review

References (32)

1. Baum, M.; Budzar, A.U.; Cuzick, J.; Forbes, J.; Houghton, J.H.; Klijn, J.G.; Sahmoud, T. ATAC Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002, 359(9324), 2131-2139. Erratum in: Lancet 2002;360(9344):1520.
2. Howell, A.; Cuzick, J.; Baum, M.; Buzdar, A.; Dowsett, M.; Forbes, J.F.; Hoctin-Boes, G.; Houghton, J.; Locker, G.Y.; Tobias, J.S. ATAC Trialists' Group. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005, 365(9453), 60-62.
3. Forbes, J.F.; Cuzick, J.; Buzdar, A.; Howell, A.; Tobias, J.S.; Baum, M. Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008, 9(1), 45-53.
4. Thürlimann, B.; Keshaviah, A.; Coates, A.S.; Mouridsen, H.; Mauriac, L.; Forbes, J.F.; Paridaens, R.; Castiglione-Gertsch, M.; Gelber, R.D.; Rabaglio, M.; Smith, I.; Wardley, A.; Price, K.N.; Goldhirsch, A. Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005, 353(26), 2747-2757. (Pubitemid 43016814)
5. BIG 1-98 Collaborative Group; Mouridsen, H.; Giobbie-Hurder, A.; Goldhirsch, A.; Thürlimann, B.; Paridaens, R.; Smith, I.; Mauriac, L.; Forbes, J.F.; Price, K.N.; Regan, M.M.; Gelber, R.D.; Coates, A.S. Letrozole therapy alone or in sequence with tamoxifen in women with breast cancer. N Engl J Med. 2009, 361(8), 766-776.
6. Thürlimann, B.; BIG 1-98 Collaborative Group. Letrozole vs. tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor positive breast cancer. Update of the BIG 1-98 primary core analysis. 11th International St. Gallen Oncology Conferences: Primary Therapy of Early Breast Cancer; March 11-14, 2009; St. Gallen, Switzerland. Abstract 0161.
7. Coombes, R.C.; Hall, E.; Gibson, L.J.; Paridaens, R.; Jassem, J.; Delozier, T.; Jones, S.E.; Alvarez, I.; Bertelli, G.; Ortmann, O.; Coates, A.S.; Bajetta, E.; Dodwell, D.; Coleman, R.E.; Fallowfield, L.J.;Mickiewicz, E.; Andersen, J.; Lønning, P.E.; Cocconi,G.; Stewart, A.; Stuart, N.; Snowdon, C.F.; Carpentieri, M.; Massimini, G.; Bliss, J.M.; van de Velde, C. Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004, 350(11), 1081-1092. Erratum in: N Engl J Med 2004;351(23):2461. (Pubitemid 38298988)
8. Coombes, R.C.; Kilburn, L.S.; Snowdon, C.F.; Paridaens, R.; Coleman, R.E.; Jones, S.E.; Jassem, J.; Van de Velde, C.J.; Delozier, T.; Alvarez, I.; Del Mastro, L.; Ortmann, O.; Diedrich, K.; Coates, A.S.; Bajetta, E.; Holmberg, S.B.; Dodwell, D.; Mickiewicz, E.; Andersen, J.; Lønning, P.E.; Cocconi, G.; Forbes, J.; Castiglione, M.; Stuart, N.; Stewart, A.; Fallowfield, L.J.; Bertelli, G.; Hall, E.; Bogle, R.G.; Carpentieri, M.; Colajori, E.; Subar, M.; Ireland, E.; Bliss, J.M.; Intergroup Exemestane Study. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007, 369(9561), 559-570. Erratum in: Lancet 2007;369(9565):906.
9. Kaufmann, M.; Jonat, W.; Hilfrich, J.; Eidtmann, H.; Gademann, G.; Zuna, I.; von Minckwitz, G. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 2007, 25(19), 2664-2670.
10. Jakesz, R.; Gnant, M.; Greil, R.; Tausch, C.; Samonigg, H.; Kwasny, W.; Kubista, E.; Stierer, M.; Luschin, G.; Mittlboeck, M. The benefits of sequencing adjuvant tamoxifen and anastrozole in postmenopausal women with hormone-responsive early breast cancer: 5 year-analysis of ABCSG Trial 8. Breast Cancer Res Treat 2005, 94(Suppl 1), S10. Abstract 13.
11. Boccardo, F.; Rubagotti, A.; Guglielmini, P.; Fini, A.; Paladini, G.; Mesiti, M.; Rinaldini, M.; Scali, S.; Porpiglia, M.; Benedetto, C.; Restuccia, N.; Buzzi, F.; Franchi, R.; Massidda, B.; Distante, V.; Amadori, D.; Sismondi, P. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 2006, 17(Suppl 7), vii 10-vii 14.
12. Goss, P.E.; Ingle, J.N.; Martino, S.; Robert, N.J.; Muss, H.B.; Piccart, M.J.; Castiglione, M.; Tu, D.; Shepherd, L.E.; Pritchard, K.I.; Livingston, R.B.; Davidson, N.E.; Norton, L.; Perez, E.A.; Abrams, J.S.; Cameron, D.A.; Palmer, M.J.; Pater, J.L. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005, 97(17), 1262-1271.
13. Jakesz, R.; Samonigg, H.; Greil, R.; Gnant, M.; Schmid, M.; Kwasny, W.; Kubista, E.; Mlineritsch, B.; Tausch, C.; Stierer, M.; on behalf of the ABCSG Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J Clin Oncol 2005, 23(16S), 10s. Abstract 527.
14. Mamounas, E.P.; Jeong, J.H.; Wickerham, D.L.; Smith, R.; Geyer, C.; Ganz, P.; Land, S.; Hutchins, L.; Eisen, A.; Ingle, J.; Costantino, J.; Wolmark, N. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol 2008, 26(12), 1965-1971.
15. Goldhirsch, A.; Wood, W.C.; Gelber, R.D.; Coates, A.S.; Thürlimann, B.; Senn, H.J. 10th St. Gallen conference. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol 2007, 18(7), 1133-1144. Erratum in: Ann Oncol 2007;18(11): 1917.
16. Winer, E.P.; Hudis, C.; Burstein, H.J.; Wolff, A.C.; Pritchard, K.I.; Ingle, J.N.; Chlebowski, R.T.; Gelber, R.; Edge, S.B.; Gralow, J.; Cobleigh, M.A.; Mamounas, E.P.; Goldstein, L.J.; Whelan, T.J.; Powles, T.J.; Bryant, J.; Perkins, C.; Perotti, J.; Braun, S.; Langer, A.S.; Browman, G.P.; Somerfield, M.R. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol 2005, 23(3), 619-629.
17. Goldhirsch, A.; Ingle, J.N.; Gelber, R.D.; Coates, A.S.; Thürlimann, B.; Senn, H.J.; Panel members. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 2009, 20(8), 1319-1329.
18. Pritchard, K.I. Aromatase inhibitors in adjuvant therapy of breast cancer: before, instead of, or beyond tamoxifen. J Clin Oncol 2005, 23(22), 4850-4852.
19. Jakesz, R.; Gnant, M.; Griel, R.; Tausch, C.; Samonigg, H.; Kwansy, W.; Kubista, E.; Stierer, M.; Luschin, G.; Rucklinger, E.; Mittibock, M. Tamoxifen and anastrozole as a sequencing strategy in postmenopausal women with hormone-responsive early breast cancer: updated data from the Austrian breast and colorectal cancer study group trial 8. Cancer Res 2009, 69(Suppl 2), 67s. Abstract 14.
20. Jakesz, R.; Jonat, W.; Gnant, M.; Mittlboeck, M.; Greil, R.; Tausch, C.; Hilfrich, J.; Kwasny, W.; Menzel, C.; Samonigg, H.; Seifert, M.; Gademann, G.; Kaufmann, M.; Wolfgang, J.; ABCSG and the GABG Switching of postmenopausal women with endocrineresponsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005, 366(9484), 455-462.
21. Cuzick, J.; Sasieni, P.; Howell, A. Should aromatase inhibitors be used as initial adjuvant treatment or sequenced after tamoxifen? Br J Cancer 2006, 94(4), 460-464.
22. Mansell, J.; Monypenny, I.J.; Skene, A.I.; Abram, P.; Carpenter, R.; Gattuso, J.M.; Wilson, C.R.; Angerson, W.J.; Doughty, J.C. Patterns and predictors of early recurrence in postmenopausal women with estrogen receptor-positive early breast cancer. Breast Cancer Res Treat. 2009, 117(1), 91-98.
23. Saphner, T.; Tormey, D.C.; Gray, R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996, 14(10), 2738-2746.
24. Dowsett, M.; Cuzick, J.; Wale, C.; Howell, T.; Houghton, J.; Baum, M. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study. J Clin Oncol 2005, 23(30), 7512-7517.
25. Dowsett, M.; Allred, C.; Knox, J.; Quinn, E.; Salter, J.; Wale, C.; Cuzick, J.; Houghton, J.; Williams, N.; Mallon, E.; Bishop, H.; Ellis, I.; Larsimont, D.; Sasano, H.; Carder, P.; Cussac, A.L.; Knox, F.; Speirs, V.; Forbes, J.; Buzdar, A. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008, 26(7), 1059-1065.
26. Viale, G.; Regan, M.M.; Maiorano, E.; Mastropasqua, M.G.; Dell'Orto, P.; Rasmussen, B.B.; Raffoul, J.; Neven, P.; Orosz, Z.; Braye, S.; Ohlschlegel, C.; Thürlimann, B.; Gelber, R.D.; Castiglione-Gertsch, M.; Price, K.N.; Goldhirsch, A.; Gusterson, B.A.; Coates, A.S. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. J Clin Oncol 2007, 25(25), 3846-3852.
27. Coates, A.S.; Keshaviah, A.; Thürlimann, B.; Mouridsen, H.; Mauriac, L.; Forbes, J.F.; Paridaens, R.; Castiglione-Gertsch, M.; Gelber, R.D.; Colleoni, M.; Ĺang, I.; Del Mastro, L.; Smith, I.; Chirgwin, J.; Nogaret, J.M.; Pienkowski, T.;Wardley, A.; Jakobsen, E.H.; Price, K.N.; Goldhirsch, A. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007, 25(5), 486-492.
28. Rasmussen, B.B.; Regan, M.M.; Lykkesfeldt, A.E.; Dell'Orto, P.; Del Curto, B.; Henriksen, K.L.; Mastropasqua, M.G.; Price, K.N.; Ḿ ery, E.; Lacroix-Triki, M.; Braye, S.; Altermatt, H.J.; Gelber, R.D.; Castiglione-Gertsch, M.; Goldhirsch, A.; Gusterson, B.A.; Thürlimann, B.; Coates, A.S.; Viale, G.; BIG 1-98 Collaborative and International Breast Cancer Study Groups. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrineresponsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 2008, 9(1): 23-28.
29. Cuzick, J. Forest plots and the interpretation of subgroups. Lancet 2005, 365(9467), 1308.
30. Punt, C.J.; Buyse, M.; Köhne, C.H.; Hohenberger, P.; Labianca, R.; Schmoll, H.J.; Pahlman, L.; Sobrero, A.; Douillard, J.Y. Endpoints in adjuvant treatment trials: a systematic review of the literature in colon cancer and proposed definitions for future trials. J Natl Cancer Inst 2007, 99(13), 998-1003.
31. Cuzick, J. Primary endpoints for randomised trials of cancer therapy. Lancet 2008, 371(9631), 2156-2158.
32. Hudis, C.A.; Barlow, W.E.; Costantino, J.P.; Gray, R.J.; Pritchard, K.I.; Chapman, J.A.; Sparano, J.A.; Hunsberger, S.; Enos, R.A.; Gelber, R.D.; Zujewski, J.A. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system. J Clin Oncol 2007, 25(15), 2127-2132.